Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: halozyme.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2024 | $58.00 → $62.00 | Overweight → Equal Weight | Wells Fargo |
| 9/19/2024 | $52.00 → $57.00 | Overweight → Neutral | JP Morgan |
| 6/7/2024 | $48.00 → $51.00 | Overweight → Neutral | Piper Sandler |
| 2/29/2024 | $54.00 | Outperform | TD Cowen |
| 7/24/2023 | $61.00 | Buy | H.C. Wainwright |
| 7/24/2023 | $43.00 → $45.00 | Buy → Neutral | Goldman |
| 5/10/2023 | $46.00 | Neutral → Overweight | Piper Sandler |
| 3/27/2023 | $58.00 | Buy | Berenberg |
| 3/16/2023 | $42.00 | Outperform → Market Perform | SVB Securities |
| 12/21/2022 | $53.00 → $65.00 | Overweight | Morgan Stanley |
Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271 Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.00-$4.20, Representing YOY Growth of 44%-52% SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its fina
Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032 Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027 Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ET SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today provided an update following a decision by the Opposition Division of the European Patent Office ("EPO") to revoke one of the Janssen Biotech, Inc. (Janssen) co-formulation patents for DARZALEX® (daratumumab) SC (Patent EP 3827845). "We remain confident in our strong royalty revenue projections with 8 approved partne
SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading. Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813747. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical comp
Four new targets nominated for total of six nominated targets, including FcRn (VYVGART® Hytrulo), for ENHANZE® drug delivery technology Halozyme to receive total upfront payment of $30 million for exclusive rights to targets SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to Halozyme's ENHANZE® drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery. argenx, a global immunology company, now has exclusively licensed ENHANZE® for a total o
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 20, 2024 /PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase in cancer cases and a 93% rise in cancer deaths among men by 2050. According to Our World in Data, cancer has overtaken cardiovascular diseases as the leading cause of death in several wealthy nations. Despite warnings from the American Cancer Society, which found that 44% of cancer deaths in U.S. adults are linked to lifestyle factors, troubling trends continue. Another study revealed that even light drinking is associated with an increase in cancer death
OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) with Halozyme's ENHANZE® drug delivery technology for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) as a twice-a-year, approximately 10-minute subcutaneous (SC) injection to be administered by a healthcare practitioner. "We are pleased that the subcutaneous formulation of OCREVUS, OCR
FDA approval marks first and only subcutaneous anti-PD-(L)1 cancer immunotherapy SAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs) with Halozyme's ENHANZE® drug delivery technology. Tecentriq Hybreza™ can be injected subcutaneously in approximately 7 minutes compared to 30-60 minutes for standard intravenous (IV) infusion of Tecentriq® (atezolizumab). The treatment will be available in the U.S. for all approved adult indications of intravenous Tecentriq®, including certain types of lung, liver, skin an
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to present and host investor meetings at the following investor conferences. Details of the presentations are as follow: Event: 2024 Wells Fargo Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, September 4, 2024 Presentation Time: 12:00 p.m. PT / 3:00 p.m. ET Location: Boston, MA Event: Morgan Stanley 22nd Annual Global Healthcare Conference Format: 1x1 Meetings Date: Thursday, September 5, 2024
USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 12, 2024 /PRNewswire/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns Hopkins Medicine reports that up to 80% of patients are diagnosed at advanced stages, making treatment much more challenging. A recent study in the journal Cell Genomics reveals that key protein biomarkers for early detection have been identified. According to analysts at Research Nester, the pancreatic cancer market is slated to expand by ~18% CAGR between 2024-2035, reaching US$36 billion by 2036. Biotech developers are actively w
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal Weight and set a new price target of $62.00 from $58.00 previously
JP Morgan downgraded Halozyme Therapeutics from Overweight to Neutral and set a new price target of $57.00 from $52.00 previously
Piper Sandler downgraded Halozyme Therapeutics from Overweight to Neutral and set a new price target of $51.00 from $48.00 previously
TD Cowen initiated coverage of Halozyme Therapeutics with a rating of Outperform and set a new price target of $54.00
H.C. Wainwright initiated coverage of Halozyme Therapeutics with a rating of Buy and set a new price target of $61.00
Goldman downgraded Halozyme Therapeutics from Buy to Neutral and set a new price target of $45.00 from $43.00 previously
Piper Sandler upgraded Halozyme Therapeutics from Neutral to Overweight and set a new price target of $46.00
Berenberg resumed coverage of Halozyme Therapeutics with a rating of Buy and set a new price target of $58.00
SVB Securities downgraded Halozyme Therapeutics from Outperform to Market Perform and set a new price target of $42.00
Morgan Stanley resumed coverage of Halozyme Therapeutics with a rating of Overweight and set a new price target of $65.00 from $53.00 previously
10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
144 - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
ARS - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
DEFA14A - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271 Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.00-$4.20, Representing YOY Growth of 44%-52% SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its fina
Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032 Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027 Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ET SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today provided an update following a decision by the Opposition Division of the European Patent Office ("EPO") to revoke one of the Janssen Biotech, Inc. (Janssen) co-formulation patents for DARZALEX® (daratumumab) SC (Patent EP 3827845). "We remain confident in our strong royalty revenue projections with 8 approved partne
SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading. Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813747. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical comp
Total Revenue of $231 million; Net Income of $93 million; Adjusted EBITDA of $137 million; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.911 Royalty Revenue Increased 12% YOY to $125 million Partner Approvals for Ocrevus® SC in Europe and the UK and VYVGART® Hytrulo for CIDP in the U.S. Maintain Recently Increased 2024 Financial Guidance: Total Revenue of $935 - $1,015 million, Representing YOY Growth of 13% - 22%, Adjusted EBITDA of $555 - $615 million, Representing YOY Growth of 30% - 44% and Non-GAAP Diluted EPS of $3.65 - $4.05, Representing YOY Growth of 32% - 46% SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") t
SAN DIEGO, July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating results on Tuesday, August 6, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, August 6, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I8719057. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company a
Company Granted New European Patent for ENHANZE® Drug Delivery Platform SAN DIEGO, June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that the Company is raising its full year 2024 financial guidance and updating its 5-year financial outlook based on the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. "We are pleased to be able to raise our full year 2024
Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ET SAN DIEGO, June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. "This new European patent for ENHANZE further strengthens our robust patent estate and extends the durability of our portfolio," said Dr. Helen Torley, president and chief ex
Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.791 Royalty Revenue Increased 21% YOY to $121 million Reiterating 2024 Financial Guidance: Total Revenue of $915 - $985 million, Representing YOY Growth of 10% - 19%, Adjusted EBITDA of $535 - $585 million, Representing YOY Growth of 26% - 37% and Non-GAAP Diluted EPS of $3.55 - $3.90, Representing YOY Growth of 28% - 41% Announced New $750 million Share Repurchase Program SAN DIEGO, May 7, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results fo
SAN DIEGO, April 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, May 7, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I871907. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancin
Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41% Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non-GAAP Diluted EPS of $0.821 Full Year 2023 Revenue Increased 26% YOY to $829 million; GAAP Diluted EPS of $2.10 and Non-GAAP Diluted EPS of $2.771 Announcing New $750 million Share Repurchase Program SAN DIEGO, Feb. 20, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating
SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
Goldman Sachs analyst Graig Suvannavejh maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $44 to $49.
Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 10 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 3 0 0 0 0 2M Ago 3 1 1 0 0 3M Ago 3 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $57.69, a high estimate of $71.00, and a low estimate of $50.00. This upward trend is evident, with the
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 price target.
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 price target.
Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $50 to $60.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS® SC is a 10-minute injection that maintains the same twice-yearly schedule as the approved IV infusion. The SC injection was designed to be administered by healthcare professionals, with the flexibility to be administered either in the clinic or in settings outside the clinic. "With OCREVUS SC, multiple sclerosi
Throughout the last three months, 12 analysts have evaluated Halozyme Therapeutics (NASDAQ:HALO), offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 9 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 1 1 0 0 2M Ago 4 1 0 0 0 3M Ago 2 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $55.0, a high estimate of $71.00, and a low estimate of $50.00. Witnessing a positive shift, the cu
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 price target.
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares soared 29.13% in the last week after reporting that its transfusion-dependent (TD) alpha-or beta-thalassemia study met primary endpoint. Several analysts raised their forecasts after the announcement. Verint Systems Inc. (NASDAQ:VRNT) shares are zoomed 22.40% after the company on Tuesday reported better-than-expected Q1 financial results and issued strong FY25 guidance. Novavax Inc (NASDAQ:NVAX) shares gained 21.54% in the last week after the U.S. Food and Drug Administration’s advisory committee voted to recommend updated vaccines for JN.1-line
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Matthew Boss downgraded the rating for Vail Resorts, Inc. (NYSE:MTN) from Neutral to Underweight, while cutting the price target from $217 to $176. Vail Resorts shares gained 0.6% to close at $193.95 on Thursday. See how other analysts view this stock. Morgan Stanley analyst Hamza Fodderwala downgraded Gen Digital Inc. (NASDAQ:GEN) from Overweight to Equal-Weight and slashed the price target from $28 to $27. Gen Digital shares fell 0.1% to settle at $25.44 on Thursday
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.
SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company." Ms. Duncan
SAN DIEGO, March 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced the appointment of Moni Miyashita to its board of directors. Ms. Miyashita is an accomplished executive with over 25 years of global strategic, mergers & acquisitions and business transformation expertise. "We are delighted to welcome an executive with Moni's broad experience and strategic vision to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Moni's deep experience in corporate strategy, mergers & acquisitions and risk management across multiple industries strongly complements our board's expertise as we focus on expanding and extending the growth oppor
SAN DIEGO, Feb. 2, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial officer, effective immediately. Ms. LaBrosse will succeed Elaine Sun, who is stepping down to pursue another opportunity. Ms. LaBrosse brings over 18 years of public accounting and corporate finance experience to Halozyme. Ms. LaBrosse joined Halozyme in 2015 and has since held roles of growing responsibility within the Company. Most recently, Ms. LaBrosse served as Halozyme's vice president, finance and accounting since 2020. Previously, Ms. LaBrosse held the role of executive director, controll
SAN DIEGO, Dec. 13, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 3, 2022. Mr. Snyder will succeed Masaru Matsuda, who is stepping down to pursue another opportunity. Mr. Snyder brings almost thirty years of legal and business experience to Halozyme. Over his career he has led and played key roles in a broad range of intellectual property, licensing, regulatory, anti-trust and litigation matters. Most recently Mr. Snyder served as senior vice president, deputy general counsel, litigation for Qualcomm Incorporated,
SAN DIEGO, Jan. 11, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today introduced 2021 financial guidance and commented on its outlook for the year. "2020 was a year of tremendous accomplishment at Halozyme highlighted by our successful transition to revenue growth and profitability, 2 U.S. FDA approvals and 2 European Commission approvals for ENHANZE® partner products, and successful completion of $150 million in share repurchases in 2020," said Dr. Helen Torley, president and chief executive officer. "We are delighted with the strong first six months post launch market adoption of DARZALEX FASPRO® in the US, which drove a return to royalty revenue growth in 2020. In